Transcode Therapeutics, Inc. (RNAZ) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Transcode Therapeutics reported revenue of $0. Net income was -$34.7M, or -$52.59 per diluted share. Operating activities generated -$19.5M of cash, leaving -$19.5M of free cash flow. At fiscal year end, Transcode Therapeutics held $162.4M in total assets against $10.5M in total liabilities, including $17.8M of cash and equivalents.
Open the full interactive Transcode Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Transcode Therapeutics Key Stats
| Share Price | $1.68 |
|---|---|
| Market Cap | $1.6M |
| 52-Week Range | $1.54 – $15.23 |
| Shares Outstanding | 957,191 (basic, 2026 Q2) |
Transcode Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$6.2M | -$18.7M | -$19.4M | -$15.7M | -$28.0M |
| Pre-Tax Income | -$6.8M | -$17.6M | -$18.5M | -$16.8M | -$34.4M |
| Income Tax | $53,051 | $0 | $0 | $0 | $226,069 |
| Net Income | -$6.8M | -$17.6M | -$18.5M | -$16.8M | -$34.7M |
| Diluted EPS | -$598752.00 | -$997920.00 | -$95735.64 | -$1319.92 | -$52.59 |
Transcode Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.9M | -$13.4M | -$17.8M | -$6.8M |
| Diluted EPS | -$5.82 | -$19.49 | -$21.28 | -$7.17 |
Transcode Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $20.8M | $5.0M | $2.8M | $5.8M | $17.8M |
| Current Assets | $22.7M | $7.4M | $4.5M | $7.1M | $22.0M |
| Total Assets | $22.9M | $7.6M | $5.2M | $7.3M | $162.4M |
| Current Liabilities | $2.5M | $4.3M | $3.5M | $2.8M | $3.5M |
| Total Liabilities | $2.5M | $4.3M | $3.5M | $9.3M | $10.5M |
| Shareholders' Equity | $20.4M | $3.2M | $1.6M | -$2.0M | $10.3M |
Transcode Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$5.3M | -$15.8M | -$18.1M | -$13.3M | -$19.5M |
| Cash From Investing | -$251,820 | -$100,919 | -$35,609 | -$21,761 | -$4,436 |
| Cash From Financing | $25.5M | $5,989 | $15.9M | $16.4M | $31.5M |
| Free Cash Flow | -$5.5M | -$15.9M | -$18.1M | -$13.3M | -$19.5M |
Figures from Transcode Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Transcode Therapeutics financials page for every line item.
Transcode Therapeutics Company Profile
| Ticker | RNAZ |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001829635 |
Frequently Asked Questions
What was Transcode Therapeutics' revenue in fiscal 2025?
Transcode Therapeutics (RNAZ) reported revenue of $0 for fiscal 2025.
What is Transcode Therapeutics' annual revenue history?
Transcode Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Transcode Therapeutics' net income in fiscal 2025?
Transcode Therapeutics reported net income of -$34.7M for fiscal 2025.
What was Transcode Therapeutics' earnings per share (EPS) in fiscal 2025?
Transcode Therapeutics' diluted EPS was -$52.59 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Transcode Therapeutics generate in fiscal 2025?
Transcode Therapeutics generated -$19.5M of free cash flow in fiscal 2025.
What was Transcode Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Transcode Therapeutics reported revenue of $0.
How many shares of Transcode Therapeutics are outstanding?
Transcode Therapeutics reported a weighted average of 957,191 basic shares outstanding in 2026 Q2.
What is Transcode Therapeutics' market cap?
Based on its latest closing price, Transcode Therapeutics (RNAZ) has a market capitalization of about $1.6M.
When does Transcode Therapeutics' fiscal year end?
Transcode Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Transcode Therapeutics headquartered?
Transcode Therapeutics lists its business address in Boston, Massachusetts in its SEC filings.